JP2020536971A5 - - Google Patents

Download PDF

Info

Publication number
JP2020536971A5
JP2020536971A5 JP2020542056A JP2020542056A JP2020536971A5 JP 2020536971 A5 JP2020536971 A5 JP 2020536971A5 JP 2020542056 A JP2020542056 A JP 2020542056A JP 2020542056 A JP2020542056 A JP 2020542056A JP 2020536971 A5 JP2020536971 A5 JP 2020536971A5
Authority
JP
Japan
Prior art keywords
substituted
coor
halogen
alkyl substituted
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020542056A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020536971A (ja
JP7254821B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/056030 external-priority patent/WO2019079261A1/en
Publication of JP2020536971A publication Critical patent/JP2020536971A/ja
Publication of JP2020536971A5 publication Critical patent/JP2020536971A5/ja
Application granted granted Critical
Publication of JP7254821B2 publication Critical patent/JP7254821B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020542056A 2017-10-16 2018-10-16 抗がん剤としての環状ジヌクレオチド Active JP7254821B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762572884P 2017-10-16 2017-10-16
US62/572,884 2017-10-16
PCT/US2018/056030 WO2019079261A1 (en) 2017-10-16 2018-10-16 CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS

Publications (3)

Publication Number Publication Date
JP2020536971A JP2020536971A (ja) 2020-12-17
JP2020536971A5 true JP2020536971A5 (enExample) 2021-11-18
JP7254821B2 JP7254821B2 (ja) 2023-04-10

Family

ID=64110154

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020542056A Active JP7254821B2 (ja) 2017-10-16 2018-10-16 抗がん剤としての環状ジヌクレオチド

Country Status (7)

Country Link
US (1) US11427610B2 (enExample)
EP (1) EP3697801B1 (enExample)
JP (1) JP7254821B2 (enExample)
KR (1) KR102747388B1 (enExample)
CN (1) CN111406063B (enExample)
ES (1) ES2997757T3 (enExample)
WO (1) WO2019079261A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3694867A1 (en) 2017-10-10 2020-08-19 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
AU2018392213B2 (en) 2017-12-20 2021-03-04 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
WO2019123339A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
KR20200130362A (ko) * 2018-03-08 2020-11-18 브리스톨-마이어스 스큅 컴퍼니 항암제로서의 시클릭 디뉴클레오티드
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
US11161864B2 (en) 2018-10-29 2021-11-02 Venenum Biodesign, LLC Sting agonists
US11110106B2 (en) 2018-10-29 2021-09-07 Venenum Biodesign, LLC Sting agonists for treating bladder cancer and solid tumors
WO2021013234A1 (en) 2019-07-25 2021-01-28 Beigene, Ltd. Cyclic dinucleotides as sting agonists
JPWO2021177123A1 (enExample) * 2020-03-03 2021-09-10
IL298019A (en) 2020-05-13 2023-01-01 Massachusetts Inst Technology Compositions of polymeric microdevices and their use in cancer immunotherapy
WO2024211577A1 (en) 2023-04-05 2024-10-10 Massachusetts Institute Of Technology Hybrid polymeric systems and methods of use thereof

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060167241A1 (en) * 2003-07-15 2006-07-27 Mitsui Chemicals, Inc. Method for synthesizing cyclic bisdinucleoside
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ox40l抗體
DK1866339T3 (da) 2005-03-25 2013-09-02 Gitr Inc GTR-bindende molekyler og anvendelser heraf
DK2559690T3 (en) 2005-05-10 2016-04-25 Incyte Holdings Corp Modulators of indoleamine 2,3-dioxygenase and methods of use thereof
ES2540561T3 (es) 2005-12-20 2015-07-10 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
US20080125470A1 (en) 2006-09-19 2008-05-29 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
PT2175884T (pt) 2007-07-12 2016-09-21 Gitr Inc Terapias de combinação empregando moléculas de ligação a gitr
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
CA2932121A1 (en) 2007-11-30 2009-06-11 Newlink Genetics Corporation Ido inhibitors
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
CN103951753B (zh) 2009-09-03 2018-01-12 默沙东公司 抗‑gitr抗体
ES2601226T3 (es) 2009-10-28 2017-02-14 Newlink Genetics Corporation Derivados de imidazol como inhibidores de IDO
CN105218672A (zh) 2009-12-10 2016-01-06 霍夫曼-拉罗奇有限公司 优先结合人csf1r胞外域4的抗体及其用途
ME03447B (me) 2010-03-04 2020-01-20 Macrogenics Inc Anтitela reakтivna sa b7-нз, njihovi imunološki akтivni fragmenтi i upotreba
KR101656548B1 (ko) 2010-03-05 2016-09-09 에프. 호프만-라 로슈 아게 인간 csf-1r에 대한 항체 및 이의 용도
RU2617966C2 (ru) 2010-03-05 2017-04-28 Ф.Хоффманн-Ля Рош Аг Антитела против csf-1r человека и их применение
KR20200044999A (ko) 2010-05-04 2020-04-29 파이브 프라임 테라퓨틱스, 인크. Csf1r에 결합하는 항체들
CN105481983B (zh) 2010-09-09 2021-09-03 辉瑞公司 4-1bb结合分子
NO2694640T3 (enExample) 2011-04-15 2018-03-17
MX338353B (es) 2011-04-20 2016-04-13 Medimmune Llc Anticuerpos y otras moleculas que se unen a b7 - h1 y pd - 1.
MX356337B (es) 2011-12-15 2018-05-23 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
JP6416630B2 (ja) 2012-02-06 2018-10-31 ジェネンテック, インコーポレイテッド Csf1r阻害剤を用いるための組成物及び方法
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
HRP20191754T1 (hr) * 2012-04-17 2020-01-24 Gilead Sciences, Inc. Spojevi i postupci za antivirusno liječenje
EP2847220A1 (en) 2012-05-11 2015-03-18 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
WO2013181634A2 (en) 2012-05-31 2013-12-05 Sorrento Therapeutics Inc. Antigen binding proteins that bind pd-l1
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
TWI713436B (zh) 2012-08-31 2020-12-21 美商戊瑞治療有限公司 用結合群落刺激因子1受體(csf1r)之抗體治療病狀之方法
WO2014099824A1 (en) * 2012-12-19 2014-06-26 Board Of Regents, The University Of Texas System Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
JP6742903B2 (ja) 2013-05-02 2020-08-19 アナプティスバイオ インコーポレイティッド プログラム死−1(pd−1)に対する抗体
CN105188373B (zh) 2013-05-18 2017-09-22 艾杜罗生物科技公司 抑制“干扰素基因刺激蛋白”依赖性信号传导的组合物和方法
US9549944B2 (en) * 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
CA2913977C (en) 2013-05-31 2022-11-29 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
HRP20221262T1 (hr) 2013-09-13 2022-12-09 Beigene Switzerland Gmbh Protutijela anti-pd1 i njihova uporaba kao terapeutskih i dijagnostičkih sredstava
SI3081576T1 (sl) 2013-12-12 2019-12-31 Shanghai Hengrui Pharmaceutical Co., Ltd., Protitelo PD-1, njegov antigen-vezavni fragment in njegova medicinska uporaba
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
CN107148424B (zh) * 2014-12-16 2021-01-08 凯拉治疗股份公司 用于诱导细胞因子的环状二核苷酸
SG11201707383PA (en) 2015-03-13 2017-10-30 Cytomx Therapeutics Inc Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
BR112018002757A8 (pt) 2015-08-13 2023-04-11 Merck Sharp & Dohme Composto, composição farmacêutica, e, métodos para induzir uma resposta imune, para induzir uma produção de interferon tipo i e para tratamento de um distúrbio
NZ746112A (en) 2016-03-18 2023-01-27 Immune Sensor Llc Cyclic di-nucleotide compounds and methods of use
AU2017378782A1 (en) 2016-12-20 2019-07-04 Merck Sharp & Dohme Corp. Combinations of PD-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment
US20200113924A1 (en) 2016-12-20 2020-04-16 Merck Sharp & Dohme Corp. Cyclic dinucleotide sting agonists for cancer treatment

Similar Documents

Publication Publication Date Title
JP2020536971A5 (enExample)
JP2020536897A5 (enExample)
JP2019501204A5 (enExample)
JP2020532542A5 (enExample)
JP2020532529A5 (enExample)
KR101937501B1 (ko) 치환된 2,3-디히드로이미다조[1,2-c]퀴나졸린 염
JP2020532539A5 (enExample)
JP5881705B2 (ja) Namptの阻害のための新規化合物及び組成物
JP2009513703A5 (enExample)
JP2020529400A5 (enExample)
CN119454706A (zh) 治疗kras相关癌症的方法
JP2013056930A5 (enExample)
JP2018504418A5 (enExample)
CN114364677B (zh) 作为toll-样受体激动剂的咪唑并[4,5-c]吡啶衍生物
JP2020506951A5 (enExample)
KR101671761B1 (ko) 이미다조옥사진 화합물에 의한 항종양 효과 증강제
JP2014503567A5 (enExample)
JP2014513704A5 (enExample)
JP2010513523A5 (enExample)
JP2014518544A5 (enExample)
JP2010523681A5 (enExample)
KR20140059268A (ko) 아미노-치환된 이미다조피리다진
JP2018534289A5 (enExample)
HRP20220520T1 (hr) Ciklički dinukleotidi kao agensi protiv raka
JP2020527173A5 (enExample)